ReviewCurrent medicinal chemistry2009
Antifungal drug discovery through the study of invertebrate model hosts.
Review in Current medicinal chemistry, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 42 citations in OpenAlex.
- Alternative Non-Mammalian Animal and Cellular Methods for the Study of Host-Fungal Interactions.Journal of fungi (Basel, Switzerland) · 2023Review
- Antifungal Activity of the Phenolic Compounds Ellagic Acid (EA) and Caffeic Acid Phenethyl Ester (CAPE) against Drug-ResistantJournal of fungi (Basel, Switzerland) · 2021Article
- Review
- Epithelial Infection WithFrontiers in microbiology · 2020Article
- Regulatory mechanisms controlling morphology and pathogenesis in Candida albicans.Current opinion in microbiology · 2019Review
- The planarian Schmidtea mediterranea is a new model to study host-pathogen interactions during fungal infections.Developmental and comparative immunology · 2019Article
- An Investigation of the Potential Antifungal Properties of CNC-2 inJournal of nematology · 2017Article
- Diversity, evolution and medical applications of insect antimicrobial peptides.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2016Review
- A quantitative genome-wide RNAi screen in C. elegans for antifungal innate immunity genes.BMC biology · 2016Article
- Paracoccidioides-host Interaction: An Overview on Recent Advances in the Paracoccidioidomycosis.Frontiers in microbiology · 2015Review
- Overcoming antifungal resistance.Drug discovery today. Technologies · 2014Review
- Immune defense mechanisms in the Caenorhabditis elegans intestinal epithelium.Current opinion in immunology · 2012Review
- Experimental models of cryptococcosis.International journal of microbiology · 2012Article
- Stimulation of host immune defenses by a small molecule protects C. elegans from bacterial infection.PLoS genetics · 2012Article
- Antifungal resistance and new strategies to control fungal infections.International journal of microbiology · 2012Article
- A murine model for catheter-associated candiduria.Journal of medical microbiology · 2011Article
- Aplysqualenol A binds to the light chain of dynein type 1 (DYNLL1).Angewandte Chemie (International ed. in English) · 2011Article
- Candida albicans infection of Caenorhabditis elegans induces antifungal immune defenses.PLoS pathogens · 2011Article
- Using C. elegans for antimicrobial drug discovery.Expert opinion on drug discovery · 2011Article
- Caenorhabditis elegans-based model systems for antifungal drug discovery.Current pharmaceutical design · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 1 country.
Funding
Abstract
There is an urgent need for new antifungal agents that are both effective and non-toxic in the therapy of systemic mycoses. The model nematode Caenorhabditis elegans has been used both to elucidate evolutionarily conserved components of host-pathogen interactions and to screen large chemical libraries for novel antimicrobial compounds. Here we review the use of C. elegans models in drug discovery and discuss caffeic acid phenethyl ester, a novel antifungal agent identified using an in vivo screening system. C. elegans bioassays allow high-throughput screens of chemical libraries in vivo. This whole-animal system may enable the identification of compounds that modulate immune responses or affect fungal virulence factors that are only expressed during infection. In addition, compounds can be simultaneously screened for antifungal efficacy and toxicity, which may overcome one of the main obstacles in current antimicrobial discovery. A pilot screen for antifungal compounds using this novel C. elegans system identified 15 compounds that prolonged survival of nematodes infected with the medically important human pathogen Candida albicans. One of these compounds, caffeic acid phenethyl ester (CAPE), was an effective antifungal agent in a murine model of systemic candidiasis and had in vitro activity against several fungal species. Interestingly, CAPE is a potent immunomodulator in mammals with several distinct mechanisms of action. The identification of CAPE in a C. elegans screen supports the hypothesis that this model can identify compounds with both antifungal and host immunomodulatory activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.